- Home
- TPST vs BEAT Comparison
TPST vs BEAT Comparison
Compare TPST & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- BEAT
- Stock Information
- Founded
- TPST 2011
- BEAT 2015
- Country
- TPST United States
- BEAT United States
- Employees
- TPST N/A
- BEAT N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- TPST Health Care
- BEAT Technology
- Exchange
- TPST Nasdaq
- BEAT Nasdaq
- Market Cap
- TPST 33.0M
- BEAT 37.7M
- IPO Year
- TPST N/A
- BEAT 2021
- Fundamental
- Price
- TPST $10.93
- BEAT $1.33
- Analyst Decision
- TPST Hold
- BEAT Buy
- Analyst Count
- TPST 3
- BEAT 1
- Target Price
- TPST $30.00
- BEAT $8.00
- AVG Volume (30 Days)
- TPST 83.5K
- BEAT 119.2K
- Earning Date
- TPST 08-11-2025
- BEAT 11-06-2025
- Dividend Yield
- TPST N/A
- BEAT N/A
- EPS Growth
- TPST N/A
- BEAT N/A
- EPS
- TPST N/A
- BEAT N/A
- Revenue
- TPST N/A
- BEAT N/A
- Revenue This Year
- TPST N/A
- BEAT N/A
- Revenue Next Year
- TPST N/A
- BEAT N/A
- P/E Ratio
- TPST N/A
- BEAT N/A
- Revenue Growth
- TPST N/A
- BEAT N/A
- 52 Week Low
- TPST $5.35
- BEAT $0.91
- 52 Week High
- TPST $20.67
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- TPST 63.44
- BEAT 56.41
- Support Level
- TPST $9.90
- BEAT $1.27
- Resistance Level
- TPST $11.18
- BEAT $1.54
- Average True Range (ATR)
- TPST 0.66
- BEAT 0.10
- MACD
- TPST -0.00
- BEAT 0.02
- Stochastic Oscillator
- TPST 80.69
- BEAT 53.88
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.